Good morning, everyone, and how are you today? We are doing just fine, thank you, helped along by a warm and shiny sun enveloping the otherwise chilly Pharmalot campus. This gives us hope that spring is near. Meanwhile, though, we are keeping busy with the usual sundry tasks and firing up the trusty coffee kettle for cups of stimulation. After all, there is much to be done and, no doubt, you can relate. So here is the lovingly assembled menu of tidbits to help you along. Have a smashing day and do keep in touch….

The head of the Sandoz generic unit at Novartis (NVS) is quitting after the drug maker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spinoff or sale, Reuters tells us. Richard Francis ran the unit since 2014. Sandoz last year sold a U.S. pills and dermatology portfolio to Aurobindo and began a “de-integration” of the division from the rest of Novartis, a process that is expected to stretch into 2020 and clear the way for talks about the future of the unit. Francesco Balestrieri, who heads Sandoz in Europe, will run the business.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy